InhaleRx (ASX:IRX) Inventories, Other : A$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. InhaleRx's other inventories for the quarter that ended in Dec. 2024 was A$0.00 Mil.

InhaleRx Inventories, Other Historical Data

The historical data trend for InhaleRx's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InhaleRx Inventories, Other Chart

InhaleRx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Other

Get a 7-Day Free Trial

0.13

InhaleRx Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Inventories, Other	Get a 7-Day Free Trial												-	-	-	-	-

InhaleRx Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

InhaleRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InhaleRx Ltd (ASX:IRX) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000

Website

https://www.inhalerx.com.au

InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines